Patent Grant
10695200
Walls of the vasculature, particularly arterial walls, may develop areas of pathological dilatation called aneurysms. As is well known, aneurysms have thin, weak walls that are prone to rupturing. Aneurysms can be the result of the vessel wall being weakened by disease, injury, or a congenital abnormality. Aneurysms could be found in different parts of the body, and the most common are abdominal aortic aneurysms and brain or cerebral aneurysms in the neurovasculature. When the weakened wall of an aneurysm ruptures, it can result in death, especially if it is a cerebral aneurysm that ruptures.
Aneurysms are generally treated by excluding the weakened part of the vessel from the arterial circulation. For treating a cerebral aneurysm, such exclusion is done in many ways including: (i) surgical clipping, where a metal clip is secured around the base of the aneurysm; (ii) packing the aneurysm with small, flexible wire coils (micro-coils); (iii) using embolic materials to “fill” an aneurysm; (iv) using detachable balloons or coils to occlude the parent vessel that supplies the aneurysm; and (v) intravascular stenting.
Intravascular stents are well known in the medical arts for the treatment of vascular stenoses or aneurysms. Stents are prostheses that expand radially or otherwise within a vessel or lumen to provide therapy or support against blockage of the vessel. Methods for delivering these intravascular stents are also well known.
Various other implantable devices are used in surgical procedures. Often, these stents and other devices are coated with a coating material in order to achieve a desired therapeutic or other effect.
In accordance with some embodiments disclosed herein, a heat-treated device (e.g., stent) is provided that comprises an even coating that is substantially free of imperfections, such as lumps, fibers, webs, and/or other obstructions in the pores of the device. Such a device can be braided and/or have a flow diverting section.
Aspects of some embodiments disclosed herein recognize the existence of significant challenges in manufacturing a flow diverting device, such as a stent, that has a coating evenly applied over its surface. Hitherto, no process or device known to the Applicants has been developed that provides a device, such as a braided stent, with a coating that is evenly distributed over its surface, e.g., a coating that is devoid of imperfections, such as lumps, webs, fibers, or other obstructions in the pores of the stent.
Some embodiments disclosed herein provide a device with at least one flow diverting section that is coated and substantially free of webbing or that has a substantially uniform coating. Some embodiments relate to coating processes by which a device (e.g., a braided stent) can receive an even, generally imperfection-free coating. Additionally, some embodiments relate to methods of treatment using such coated devices (e.g., braided stents). Furthermore, some embodiments relate to one or more of the various advantageous features of the coated devices (e.g., braided stents).
For example, in some embodiments a medical device is provided for treating an aneurysm. The device can comprise a tubular body comprising a plurality of braided filaments and configured to be implanted in a blood vessel. The body can be expandable to an expanded state for treatment of the aneurysm. The body can have a first section for spanning the neck of the aneurysm and a plurality of pores located between the filaments. The pores in the first section can have a first average pore size of less than about 500 microns when the body is in the expanded state. The first section can have a substantially complete coating, comprising a coating material, over the filaments. Further, the first section can be substantially free of webs formed between the braided filaments by the coating material.
The first section can comprise a length less than an entire length of the tube. The coating material on the first section can be generally uniform over the device or filaments. The coating can comprise an antithrombogenic material.
The medical device can further comprise a second section having a plurality of pores having a second average pore size greater than the first average pore size.
Further, some embodiments can provide a delivery system for treating an aneurysm. The system can comprise a microcatheter configured to be implanted into a blood vessel, a core assembly, extending within the microcatheter, having a distal segment, and the device extending along the core assembly distal segment.
Furthermore, the medical device can comprise a tubular member having a sidewall and a plurality of pores in the sidewall that are sized to inhibit flow of blood through the sidewall into an aneurysm to a degree sufficient to lead to thrombosis and healing of the aneurysm when the tubular member is positioned in a blood vessel and adjacent to the aneurysm. The device can also have an anti-thrombogenic coating distributed over the tubular member such that the pores are substantially free of webs formed by the coating.
The pores can have an average pore size that is the average size of the pores in the first section without the coating material. The coating can be substantially complete over the device or tubular member. The coating can be generally uniform over the device or tubular member. The device or tubular member can comprise a plurality of braided filaments. The device or tubular member can be substantially free of webs formed between the braided filaments by the coating. The flow diverting pores can extend over less than a longitudinal length that is less than a longitudinal length of the device or tubular member.
The device can comprise a tubular member comprising a plurality of filaments that are braided together to form pores therebetween. The tubular member can have a flow diverting section configured to span the neck of the aneurysm. The device can also have a coating distributed over the flow diverting section. The coating is distributed completely over the flow diverting section substantially free of imperfections such that coated first and second longitudinal segments of the flow diverting section of approximately the same longitudinal lengths have approximately equal weights.
A medical device for treating an aneurysm can also be provided that comprises a tubular member comprising a plurality of filaments, formed from a first material, that are braided together to form pores therebetween. The device can also comprise a coating material distributed over the filaments to form a coated flow diverting section that is substantially free of webs formed between the filaments by the coating material. The coating material can be distributed such that the device is significantly less thrombogenic than an uncoated device formed from the first material.
The coating material can be one or more of a variety of anti-thrombogenic materials or platelet aggregation inhibitors, or anti-thrombogenic polymers or monomers. Suitable coating materials include 2-Methacryloyloxyethyl phosphorylcholine (MPC, available as LIPIDURE™ from NOF Corporation of Tokyo, Japan). A suitable form of MPC is LIPIDURE™-CM2056, or 2-Methacryloyloxyethyl phosphorylcholine-poly(n-butyl methacrylate). Additional suitable coating materials include PARYLENE C™, or PARYLENE HT™, both available from Specialty Coating Systems of Indianapolis, Ind.; BAYMEDIX™ available from Bayer AG of Leverkusen, Germany; BIOCOAT™ hyaluronic acid available from BioCoat, Inc. of Horsham, Pa.; or polyethylene oxide. Other coating materials include heparin, heparin-like materials or derivatives, hirudin, H-Heparin, HSI-Heparin, albumin, phospholipids, streptokinase, tissue plasminogen activator (TPA), urokinase, hyaluronic acid, chitosan, methyl cellulose, poly(ethylene oxide), poly(vinyl pyrrolidone), endothelial cell growth factor, epithelial growth factor, osteoblast growth factor, fibroblast growth factor, platelet derived growth factor or angiogenic growth factor.
In some embodiments, the pores can have an average pore size that is less than or equal to about 500 microns. The pores can have an average pore size that is less than or equal to about 320 microns. The pores can have an average pore size that is from about 50 microns to about 320 microns. The pores can have a pore size that is generally constant. The pores can have an average pore size that is measured using an inscribed circle diameter.
Some embodiments of processes disclosed herein comprise mounting or maintaining a braided, flow diverting device (e.g., stent) in a longitudinally stretched configuration during the coating process in order to prevent coating imperfections, such as webbing. The longitudinally stretched configuration can enable individual filaments of the braided device to overlap each other at angles of between about 75 degrees and about 105 degrees with respect to each other. The longitudinally stretched configuration can enable individual filaments of the braided device to overlap each other at angles of between about 80 degrees and about 100 degrees with respect to each other. Further, the longitudinally stretched configuration can enable individual filaments of the braided device to overlap each other at angles of between about 85 degrees and about 95 degrees with respect to each other. Furthermore, the longitudinally stretched configuration can enable individual filaments of the braided device to overlap each other approximately perpendicularly or at a generally right angles with respect to each other. In some embodiments, therefore, the longitudinally stretched configuration can orient the individual filaments to create a pattern of quadrilaterals, such as squares, rectangles, parallelograms, rhombuses, trapezoids, etc.
Further, some embodiments of processes disclosed herein comprise dipping a longitudinally stretched braided device (e.g., stent) in a coating solution and thereafter air knifing the dipped device. The process of air knifing can comprise applying at least one powerful jet of air to remove or blow off any excess solution from the device. The air jet(s) of the air knife(s) can be applied in a direction that is generally transverse, such as orthogonal, relative to the longitudinal axis of the device. The air knife can be stationary while the device is moved or it can move along and/or about the device as the device remains stationary.
In some embodiments, the longitudinally stretched braided device (e.g., stent) can alternatively be coated with a coating solution using a spraying operation. In some embodiments, while the device is being coated, the device can be rotated about its central longitudinal axis to ensure even application of the air jet or sprayed coating.
For example, a method of coating a stent is provided wherein the method comprises: attaching first and second ends of the stent with upper and lower connectors of a holder device, the stent comprising a flow diverting section; dipping the stent into a coating material to coat a first section of the stent; and removing excess coating material from the stent such that the stent is free of webs formed by the coating material.
The method can be performed such that the flow diverting section comprises a plurality of pores having an average pore size that is less than or equal to about 500 microns. Further, the average pore size can be less than or equal to about 320 microns. The average pore size can be from about 50 microns to about 320 microns.
The method can be performed such that dipping the stent into the coating material comprises dipping less than an entire length of the stent into the coating material to maintain an open air pocket adjacent to the stent first end. Further, attaching the first and second ends of the stent can comprise attaching the stent to the holder device such that the stent is held between the upper and lower connectors in a radially collapsed, longitudinally elongated state. The stent can comprise a plurality of braided filaments, and the stent filaments can cross each other at substantially right angles when the stent is held in the elongated state. Further, the elongated state can be achieved when the stent filaments cross each other at angles in an angular range from about 80° to about 110°. In addition, the stent can comprise a plurality of braided filaments, and the coating material on the stent can be substantially free of webs such that the coating material does not bridge between adjacent filaments.
Additionally, some embodiments of the coating (e.g., dipping, spraying, etc.) processes disclosed herein can be performed using a cantilevered fixture. One of the inventive realizations of some embodiments is that a cantilevered fixture, which can be suitable for use in, for example, a dipping process, can also be designed to be suitable for use in air knifing processes, when necessary. In order to be suitable for air knifing processes, however, the cantilevered fixture can beneficially be configured to resist deflection, such as the “pendulum effect” that occurs when an air jet is applied to the mounted device, and the device and the fixture begin to move back and forth harmonically, off-axis. Further, the cantilevered fixture can also beneficially be configured to mount the device thereto without passing through a lumen of the device or otherwise interfering with air flow from the air knife. Furthermore, the cantilevered fixture can also beneficially avoid contact with the device in order to prevent wicking or removing solution from the surface of the device.
Accordingly, in some embodiments, the cantilevered fixture can be both rigid and lightweight. For example, a lower (free) end of the cantilevered fixture can be lighter weight than an upper (cantilevered) end of the cantilevered fixture.
Further, in some embodiments, the cantilevered fixture can comprise first and second ends that engage with corresponding ends of the device (e.g., stent) and a fixture body that extends between the first and second ends and outside of a device lumen when the device is mounted to the fixture. The first end can comprise one or more clips or protrusions that engage a first end of the device, such as by pinching, grasping, friction, and/or hook and loop, or other mechanical fastening means. The second end can comprise one or more clips or protrusions that engage an opposing end of the device, such as by pinching, grasping, friction, and/or a hook and loop or other mechanical fastening means. The first and second ends can be upper or lower ends of the cantilevered fixture. The first and second ends can be spaced apart sufficiently to maintain the device in a longitudinally stretched configuration when mounted on the cantilevered fixture.
In accordance with some embodiments, a method of coating a stent is provided in which the method comprises: attaching a first end of the stent with an upper connector of a holder device, the stent comprising a plurality of braided filaments; attaching a second end of the stent with a lower connector of the holder device such that the stent is held between the upper and lower connectors in a radially collapsed, longitudinally elongated state, the stent filaments crossing each other at substantially right angles when the stent is held in the elongated state; while maintaining the stent in the elongated state, dipping the stent into a coating material to coat a first section of the stent; and removing excess coating material from the stent.
The elongated state can be achieved when the stent filaments cross each other at angles ranging from about 80° to about 110°. Further, the elongated state can be achieved when the stent filaments cross each other at angles in a range from about 85° to about 95°.
The method can be performed such that removing excess coating material comprises applying a stream of gas to the stent filaments. The stream of gas can be of a sufficient strength to remove excess coating material from the stent. Further, removing excess coating material can comprise rotating the stent and holder device while applying a stream of gas to impinge upon an outer surface of the stent. Furthermore, the method can comprise drying the coating material applied to the stent. For example, the drying can comprise drying the stent in an oven at between from about 50° to about 80° for between from about 5 minutes to about 1 hour, and in some embodiments, at about 60° for about 15 minutes.
The method can be performed such that dipping the stent into the coating material comprises dipping less than an entire length of the stent into the coating material to maintain an open air pocket adjacent to the stent first end. Further, the holder device upper and lower connectors can be interconnected such that the holder device is in a cantilevered configuration during the dipping and removing steps.
In some embodiments, a method of coating a stent can be provided that comprises: attaching a first end of the stent with an upper connector of a holder device, the stent comprising a plurality of braided filaments and a plurality of pores located between the filaments; attaching a second end of the stent with a lower connector of the holder device such that the stent is held between the upper and lower connectors in a radially collapsed, longitudinally elongated state in which the filaments are oriented to substantially maximize an average inscribed area of the pores; while maintaining the stent in the elongated state, dipping the stent into a coating material to coat a first section of the stent; and removing excess coating material from the stent.
The method can be performed such that the maximum average inscribed area of the pores is achieved when the filaments cross each other at substantially right angles. The maximum average inscribed area of the pores can be achieved when the pores are substantially square. The maximum average inscribed area of the pores can be achieved when the filaments cross each other at angles in a range from about 80° to about 110°. Further, the maximum average inscribed area of the pores can be achieved when the filaments cross each other at angles in a range from about 85° to about 95°.
The subject technology is illustrated, for example, according to various aspects described below. Various examples of aspects of the subject technology are described as numbered clauses (1, 2, 3, etc.) for convenience. These are provided as examples and do not limit the subject technology. It is noted that any of the dependent clauses may be combined in any combination, and placed into a respective independent clause, e.g., clause 1 or clause 5. The other clauses can be presented in a similar manner.
Clause 1. A medical device for treating an aneurysm, comprising:
Clause 2. The medical device of Clause 1, wherein the first average pore size is less than or equal to about 320 microns.
Clause 3. The medical device of Clause 2, wherein the first average pore size is from about 50 microns to about 320 microns.
Clause 4. The medical device of Clause 1, wherein the first average pore size is measured using an inscribed circle diameter.
Clause 5. The medical device of Clause 1, wherein the first average pore size is the average size of the pores in the first section without the coating material.
Clause 6. The medical device as in Clause 1, wherein the first section comprises less than an entire length of the tube.
Clause 7. The medical device as in Clause 1, wherein the coating material on the first section is generally uniform over the filaments.
Clause 8. The medical device as in Clause 1, wherein the coating comprises an antithrombogenic material.
Clause 9. The medical device as in Clause 8, wherein the coating comprises an antithrombogenic polymer.
Clause 10. The medical device as in Clause 8, wherein the coating comprises MPC.
Clause 11. The medical device as in Clause 1, further comprising a second section having a plurality of pores having a second average pore size greater than the first average pore size.
Clause 12. The medical device as in Clause 1, wherein the first section comprises a circumferential portion of the device that is at least 5 mm in length.
Clause 13. A delivery system for treating an aneurysm, the system comprising:
a microcatheter configured to be implanted into a blood vessel;
a core assembly, extending within the microcatheter, having a distal segment; and
the device of Clause 1 extending along the core assembly distal segment.
Clause 14. The medical device as in Clause 1, wherein the filaments comprise heat-treated metallic filaments.
Clause 15. The medical device as in Clause 1, wherein the tubular body comprises a heat-set metallic braid.
Clause 16. The medical device as in Clause 1, wherein the tubular body is self-expanding.
Clause 17. The medical device as in Clause 1, wherein the device is less thrombogenic than an identical, uncoated device.
Clause 18. The medical device as in Clause 17, wherein the device exhibits an elapsed time before peak thrombin formation that is at least 1.5 times the elapsed time of the identical, uncoated device.
Clause 19. The medical device as in Clause 1, wherein the tubular body has an open proximal end, an open distal end, and forms a lumen extending from the proximal end to the distal end.
Clause 20. A medical device for treating an aneurysm, comprising:
Clause 21. The medical device of Clause 20, wherein the pores have an average pore size that is less than or equal to about 500 microns.
Clause 22. The medical device of Clause 21, wherein the pores have an average pore size that is less than or equal to about 320 microns.
Clause 23. The medical device of Clause 22, wherein the pores have an average pore size that is from about 50 microns to about 320 microns.
Clause 24. The medical device of Clause 20, wherein the pores have an average pore size that is measured using an inscribed circle diameter.
Clause 25. The medical device of Clause 20, wherein the pores have an average pore size that is the average size of the pores in the first section without the coating material.
Clause 26. The device of Clause 20, wherein the coating is substantially complete over the tubular member.
Clause 27. The device of Clause 26, wherein the coating is generally uniform over the tubular member.
Clause 28. The device of Clause 20, wherein the coating is substantially complete over at least a circumferential section of the device that is 5 mm or more in length.
Clause 29. The medical device of Clause 20, wherein the tubular member comprises a plurality of braided filaments.
Clause 30. The medical device as in Clause 29, wherein the filaments comprise heat-treated metallic filaments.
Clause 31. The medical device as in Clause 29, wherein the tubular member comprises a heat-set metallic braid.
Clause 32. The medical device as in Clause 29, wherein the tubular member is substantially free of webs formed between the braided filaments by the coating.
Clause 33. The medical device as in Clause 20, wherein the tubular member is self-expanding.
Clause 34. The medical device of Clause 20, wherein the flow diverting pores extend over less than a longitudinal length that is less than a longitudinal length of the tubular member.
Clause 35. The medical device as in Clause 20, wherein the device is less thrombogenic than an identical, uncoated device.
Clause 36. The medical device as in Clause 35, wherein the device exhibits an elapsed time before peak thrombin formation that is at least 1.5 times the elapsed time of the identical, uncoated device.
Clause 37. The medical device as in Clause 20, wherein the tubular body has an open proximal end, an open distal end, and forms a lumen extending from the proximal end to the distal end.
Clause 38. A medical device for treating an aneurysm, comprising:
Clause 39. The medical device of Clause 38, wherein the pores in the flow diverting section have an average pore size that is less than or equal to about 500 microns.
Clause 40. The medical device of Clause 39, wherein the average pore size is less than or equal to about 320 microns.
Clause 41. The medical device of Clause 40, wherein the average pore size is from about 50 microns to about 320 microns.
Clause 42. The medical device of Clause 38, wherein the pores in the flow diverting section have a pore size that is generally constant.
Clause 43. The medical device of Clause 38, wherein the coating is generally uniform over the flow diverting section.
Clause 44. The medical device as in Clause 38, wherein the filaments comprise heat-treated metallic filaments.
Clause 45. The medical device as in Clause 38, wherein the tubular member comprises a heat-set metallic braid.
Clause 46. A method of coating a stent, the method comprising:
Clause 47. The method of Clause 46, wherein the flow diverting section comprises a plurality of pores having an average pore size that is less than or equal to about 500 microns.
Clause 48. The method of Clause 47, wherein the average pore size is less than or equal to about 320 microns.
Clause 49. The method of Clause 48, wherein the average pore size is from about 50 microns to about 320 microns.
Clause 50. The method of Clause 46, wherein dipping the stent into the coating material comprises dipping less than an entire length of the stent into the coating material to maintain an open air pocket adjacent to the stent first end.
Clause 51. The method of Clause 46, wherein attaching the first and second ends of the stent comprises attaching the stent to the holder device such that the stent is held between the upper and lower connectors in a radially collapsed, longitudinally elongated state.
Clause 52. The method of Clause 51, wherein the stent comprises a plurality of braided filaments, and wherein the stent filaments cross each other at substantially right angles when the stent is held in the elongated state.
Clause 53. The method of Clause 52, wherein the elongated state is achieved when the stent filaments cross each other at angles in an angular range from about 80° to about 110°.
Clause 54. The method of Clause 46, wherein the stent comprises a plurality of braided filaments, and the coating material on the stent is substantially free of webs such that the coating material does not bridge between adjacent filaments.
Clause 55. A method of coating a stent, the method comprising:
Clause 56. The method of Clause 55, wherein the elongated state is achieved when the stent filaments cross each other at angles in an angular range from about 80° to about 110°.
Clause 57. The method of Clause 56, wherein the elongated state is achieved when the stent filaments cross each other at angles in an angular range from about 85° to about 95°.
Clause 58. The method of Clause 55, wherein removing excess coating material comprises applying a stream of gas to the stent filaments, the stream of gas being of a sufficient strength to remove excess coating material from the stent.
Clause 59. The method of Clause 55, wherein removing excess coating material comprises rotating the stent and holder device while applying a stream of gas to impinge upon an outer surface of the stent.
Clause 60. The method of Clause 55, further comprising drying the coating material applied to the stent.
Clause 61. The method of Clause 55, wherein dipping the stent into the coating material comprises dipping less than an entire length of the stent into the coating material to maintain an open air pocket adjacent to the stent first end.
Clause 62. The method of Clause 55, wherein the holder device upper and lower connectors are interconnected such that the holder device is in a cantilevered configuration during the dipping and removing steps.
Clause 63. A method of coating a stent, the method comprising:
Clause 64. The method of Clause 63, wherein the maximum average inscribed area of the pores is achieved when the filaments cross each other at substantially right angles.
Clause 65. The method of Clause 63, wherein the maximum average inscribed area of the pores is achieved when the pores are substantially square.
Clause 66. The method of Clause 63, wherein the maximum average inscribed area of the pores is achieved when the filaments cross each other at angles in an angular range from about 80° to about 110°.
Clause 67. The method of Clause 66, wherein the maximum average inscribed area of the pores is achieved when the filaments cross each other at angles in an angular range from about 85° to about 95°.
Clause 68. A medical device for treating an aneurysm, the device comprising:
Clause 69. The device of Clause 68, wherein the coating material comprises an antithrombogenic polymer.
Clause 70. The device of Clause 68, wherein the coating material comprises MPC.
Clause 71. The device of Clause 68, wherein the coating material comprises MPC.
Clause 72. The device of Clause 68, wherein the filaments comprise heat-treated metallic filaments.
Clause 73. The medical device as in Clause 68, wherein the tubular member is self-expanding.
Clause 74. The medical device as in Clause 68, wherein the device exhibits an elapsed time before peak thrombin formation that is at least 1.5 times the elapsed time of the similar, uncoated device.
Clause 75. A method of treating an aneurysm formed in a wall of a parent blood vessel, the method comprising:
Clause 76. A method of treating an aneurysm formed in a wall of a parent blood vessel of a patient, the method comprising:
Clause 77. The method of Clause 76, wherein the stent comprises the medical device of any preceding Clause.
Clause 78. The method of Clause 76, wherein the patient is one who has been diagnosed as being at risk of an intracranial hemorrhage.
Clause 79. The method of Clause 76, wherein the patient is one who has been diagnosed as being at risk of a cerebral hemorrhage from an aneurysm.
Clause 80. The method of Clause 76, wherein the parent blood vessel is an intracranial artery.
Clause 81. The method of Clause 76, further comprising accessing a treatment region near the aneurysm by inserting a microcatheter into the parent vessel, and delivering the stent through the microcatheter to the treatment region.
Clause 82. The method of Clause 76, wherein the stent exhibits an elapsed time before peak thrombin formation that is at least 1.5 times the elapsed time of the similar but uncoated stent.
Clause 83. A method of treating an aneurysm formed in a wall of a parent blood vessel of a patient, the method comprising:
Clause 84. The method of Clause 83, wherein the stent comprises the medical device of any preceding Clause.
Clause 85. The method of Clause 83, wherein the patient is one who has been diagnosed as being at risk of an intracranial hemorrhage.
Clause 86. The method of Clause 83, wherein the patient is one who has been diagnosed as being at risk of a cerebral hemorrhage from an aneurysm.
Clause 87. The method of Clause 83, wherein the parent blood vessel is an intracranial artery.
Clause 88. The method of Clause 83, further comprising accessing a treatment region near the aneurysm by inserting a microcatheter into the parent vessel, and delivering the stent through the microcatheter to the treatment region.
Clause 89. A medical device for treating an aneurysm, comprising:
a tubular member comprising a plurality of braided filaments that form a sidewall and a plurality of pores in the sidewall that are sized to inhibit flow of blood through the sidewall into an aneurysm to a degree sufficient to lead to thrombosis and healing of the aneurysm when the tubular member is positioned in a blood vessel and adjacent to the aneurysm; and
an anti-thrombogenic material distributed over the tubular member such that the pores are substantially free of webs formed by the material;
wherein the tubular member exhibits an elapsed time before peak thrombin formation that is at least 1.5 times the elapsed time of an identical, uncoated tubular member.
Clause 90. The medical device of Clause 89, wherein the pores have an average pore size that is less than or equal to about 500 microns.
Clause 91. The medical device of Clause 89, wherein the pores have an average pore size that is less than or equal to about 320 microns.
Clause 92. The medical device of Clause 91, wherein the pores have an average pore size that is measured using an inscribed circle diameter.
Clause 93. The medical device of Clause 89, wherein the distribution of the anti-thrombogenic material is substantially complete over the tubular member.
Clause 94. The medical device of Clause 93, wherein the anti-thrombogenic material is generally uniform over the tubular member.
Clause 95. The medical device of Clause 89, wherein the distribution of the anti-thrombogenic material is substantially complete over at least a circumferential section of the tubular member that is 5 mm or more in length.
Clause 96. The medical device of Clause 95, wherein the anti-thrombogenic material comprises an anti-thrombogenic polymer.
Clause 97. The medical device of Clause 96, wherein the anti-thrombogenic polymer comprises MPC.
Clause 98. The medical device of Clause 89, wherein the tubular member comprises a heat-set metallic braid.
Clause 99. The medical device of Clause 89, wherein the tubular member is self-expanding.
Clause 100. The medical device of Clause 89, wherein the tubular member has an open proximal end, an open distal end, and forms a lumen extending from the proximal end to the distal end.
Clause 101. The medical device of Clause 89, wherein the tubular member exhibits an elapsed time before peak thrombin formation that is at least 2.5 times the elapsed time of an identical, uncoated tubular member.
Clause 102. The medical device of Clause 89, wherein the tubular member has an expanded diameter, and an unexpanded diameter smaller than the expanded diameter, and the unexpanded diameter is 5 mm or less.
Clause 103. The medical device of Clause 102, wherein the unexpanded diameter is 3 mm or less.
Clause 104. A delivery system for treating an aneurysm, the system comprising:
an elongate core assembly comprising a tube, a wire, or a combination of a tube and a wire; and
the medical device of Clause 89 engaged with the core assembly so as to be movable via the core assembly.
Clause 105. The delivery system of Clause 104, further comprising a microcatheter configured to be implanted into a blood vessel, wherein the core assembly is configured to extend within the microcatheter.
Clause 106. The delivery system of Clause 104, further comprising a polymeric member that engages an inner wall of the tubular body and enables longitudinal force transmission from the core assembly to the tubular body.
Clause 107. A medical device for treating an aneurysm, comprising:
a tubular body configured to be implanted in a blood vessel and comprising a plurality of braided filaments, the body being expandable to an expanded state for treatment of the aneurysm, the body having a first section for spanning the neck of the aneurysm and a plurality of pores located between the filaments, the pores in the first section having a first average pore size of less than about 500 microns when the body is in the expanded state;
the first section having a substantially complete distribution of anti-thrombogenic material over the filaments;
wherein the first section is substantially free of webs formed between the braided filaments by the anti-thrombogenic material;
wherein the tubular body exhibits an elapsed time before peak thrombin formation that is at least 1.5 times the elapsed time of an identical, uncoated tubular body.
Clause 108. The medical device of Clause 107, wherein the first average pore size is less than or equal to about 320 microns.
Clause 109. The medical device of Clause 107, wherein the first average pore size is measured using an inscribed circle diameter.
Clause 110. The medical device of Clause 107, wherein the first average pore size is the average size of the pores in the first section without the anti-thrombogenic material.
Clause 111. The medical device of Clause 107, wherein the first section comprises less than an entire length of the tube.
Clause 112. The medical device of Clause 107, wherein the anti-thrombogenic material on the first section is generally uniform over the filaments.
Clause 113. The medical device of Clause 107, wherein the anti-thrombogenic material comprises an anti-thrombogenic polymer.
Clause 114. The medical device of Clause 113, wherein the anti-thrombogenic polymer comprises MPC.
Clause 115. The medical device of Clause 107, wherein the tubular body comprises a heat-set metallic braid.
Clause 116. The medical device of Clause 107, wherein the tubular body is self-expanding.
Clause 117. The medical device of Clause 107, wherein the tubular body has an open proximal end, an open distal end, and forms a lumen extending from the proximal end to the distal end.
Clause 118. The medical device of Clause 107, wherein the tubular body exhibits an elapsed time before peak thrombin formation that is at least 2.5 times the elapsed time of an identical, uncoated tubular member.
Clause 119. The medical device of Clause 107, wherein the tubular body has an expanded diameter, and an unexpanded diameter smaller than the expanded diameter, and the unexpanded diameter is 5 mm or less.
Clause 120. The medical device of Clause 119, wherein the unexpanded diameter is 3 mm or less.
Clause 121. A delivery system for treating an aneurysm, the system comprising:
an elongate core assembly comprising a tube, a wire, or a combination of a tube and a wire; and
the medical device of Clause 107 engaged with the core assembly so as to be movable via the core assembly.
Clause 122. The delivery system of Clause 121, further comprising a microcatheter configured to be implanted into a blood vessel, wherein the core assembly is configured to extend within the microcatheter.
Clause 123. The delivery system of Clause 121, further comprising a polymeric member that engages an inner wall of the tubular body and enables longitudinal force transmission from the core assembly to the tubular body.
Additional features and advantages of the subject technology will be set forth in the description below, and in part will be apparent from the description, or may be learned by practice of the subject technology. The advantages of the subject technology will be realized and attained by the structure particularly pointed out in the written description and embodiments hereof as well as the appended drawings.
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory and are intended to provide further explanation of the subject technology.
The accompanying drawings, which are included to provide further understanding of the subject technology and are incorporated in and constitute a part of this specification, illustrate aspects of the disclosure and together with the description serve to explain the principles of the subject technology.
In the following detailed description, numerous specific details are set forth to provide a full understanding of the subject technology. It should be understood that the subject technology may be practiced without some of these specific details. In other instances, well-known structures and techniques have not been shown in detail so as not to obscure the subject technology. Further, although the present disclosure may refer to embodiments in which the apparatus is a stent, aspects of the embodiments disclosed herein can be used with any implantable device, such as coils, filters, scaffolds, self-expanding and balloon-expandable stents, and other devices.
In accordance with some embodiments disclosed herein, a heat-treated device (e.g., stent) is provided that comprises an even coating that is substantially free of imperfections, such as lumps, fibers, webs, and/or other obstructions in the pores of the device. Further, in some embodiments, such a device can be braided and/or have a flow diverting section.
To the Applicants' knowledge, the devices and methods disclosed herein have not been available or possible based on prior devices and methods of manufacture. In general, prior coated devices, such as stents, have demonstrated various coating imperfections and resultant disadvantages.
Among these disadvantages, “webbing,” delamination, and uneven layering of coating material pose significant risks. “Webbing” of coating material occurs when the coating material spans or extends between filaments of a device to create a thin, localized film of coating material between the filaments. Delamination occurs when coating material peels away from or is not bound to the device filaments. Uneven layering of coating material can exacerbate the effects of delamination and webbing, creating large pieces of coating that do not easily dissolve or pass through a blood vessel when such pieces are dislodged. Webbing and delamination create a significant risk to proper blood flow if that coating material is dislodged or breaks free from the device filaments. If this occurs, the dislodged coating material can create or contribute to blockages in the blood vessel. This is a dangerous condition that can result from certain prior art devices and coating processes.
For example, referring to
Typically, a braided vascular device such as a stent is braided from filaments which are formed from metal alloys and/or other high-temperature materials. The resulting braid is then heat-treated or “heat-set” at high temperature in order to reduce internal stresses in the filaments and increase the self-expanding capability of the stent. The prevalence of heat treatment and need for self-expanding properties in the manufacture of braided vascular devices and stents negates the possibility of “pre-coating” the individual filaments with a low-temperature material such as a polymer, a drug or a drug carrier and then braiding the pre-coated filaments to form a device which must then be heat-treated. Truly, a person of skill has had no expectation of successfully braiding filaments that have been pre-coated with any of the low-temperature materials that make up the bulk of useful coatings, and later heat setting the braided device to create a coated, heat-set device because of the significant damage the heat would cause to the coating.
Furthermore, no prior device or method of manufacturing known to the Applicants has been able to produce a heat-treated, coated, braided implantable device with a small pore size that is free of the disadvantages of webbing, delamination, and uneven layering of coating material, which is now possible in accordance with some implementations of the present disclosure. Again, given the exceedingly small pore size, a person of skill has had no expectation of successfully coating such a device evenly and without the disadvantages of webbing, delamination, or other coating imperfections.
Indeed, to the present knowledge of the Applicants, no prior devices or methods of manufacture have been developed that produce a coated device (e.g., stent) having a flow diverting section that is substantially free of the disadvantages noted above. As discussed herein, a flow diverting section can have pores with a “flow diverting pore size.” A “flow diverting pore size” can refer to an average pore size of pores (in at least a section of a device) that is sufficiently small enough to interfere with or inhibit fluid exchange through the pores of that section. For example, a device (e.g., stent) can have an active section or a flow diverting section with a flow diverting pore size when the pores of the section are sized to inhibit flow of blood through the sidewall into an aneurysm to a degree sufficient to lead to thrombosis and healing of the aneurysm when the tubular member is positioned in a blood vessel and adjacent to or across the neck of the aneurysm.
For example, a flow diverting pore size can be achieved when pores in the flow diverting or active section (or in the stent as a whole) have an average pore size of less than about 500 microns when the device (e.g., stent) is in the expanded state. (When “expanded state” is used herein to specify braided stent parameters such as pore sizes, the expanded state is one that the stent will self-expand to without any external expansive forces applied, and without any external longitudinal stretching or compressive forces applied. For simplicity of measurement, this expanded state can be one that the stent will self-expand to within a straight glass cylindrical tube with an inside diameter that is smaller than the maximum diameter to which the stent will self-expand in the absence of any containment or external forces.) In some embodiments, the average pore size can be less than about 320 microns. Indeed, because of such exceedingly small average pore sizes, any known prior device or attempt at manufacturing such a device resulted in substantial webbing, delamination, and uneven application of coating to the device. In contrast, some embodiments disclosed herein enable and provide a device and methods of manufacturing in which the device has a flow diverting section that is substantially free of webbing, delamination, and other coating deficiencies.
Accordingly, some embodiments provide a device, such as a braided stent, that can have a flow diverting section or other portion of the device that provides embolic properties so as to interfere with blood flow in (or into) the body space (e.g., an aneurysm) in (or across) which the device is deployed. The porosity and/or pore size of one or more sections of the device can be selected to interfere with blood flow to a degree sufficient to thrombose the aneurysm or other body space.
For example, some embodiments provide a device (e.g., stent) that can be configured to interfere with blood flow to generally reduce the exchange of blood between the parent vessel and an aneurysm, which can induce thrombosis of the aneurysm. A device (or a device component, such as a sidewall of a stent or a section of such a sidewall) that thus interferes with blood flow can be said to have a “flow diverting” property.
Additionally, in some embodiments, a device (e.g., stent) can be provided with a porosity in the range of 5%-95% may be employed in the expanded braid. In some embodiments, a porosity in the range of 30%-90% may be employed. Further, a porosity in the range of 50%-85% may be employed.
Further, in some embodiments, a device (e.g., stent) can be provided with a pore size in the range of 20-300 microns (inscribed diameter). In some embodiments, a pore size in the range of 25-250 microns (inscribed diameter) may be employed. In some embodiments, a pore size in the range of 50-200 microns (inscribed diameter) may be employed.
Methods of treatment and methods of manufacturing embodiments of the devices (e.g., stents) disclosed herein are also provided. Therefore, various embodiments of the devices disclosed herein address the problems and complications associated with unevenly and improperly coated devices (e.g., stents) and provide novel processes for manufacturing and using such devices.
Some embodiments of processes disclosed herein comprise mounting or maintaining a braided device (e.g., stent) in a longitudinally stretched configuration during the coating process. Such a device can have an expanded configuration in which the pores thereof are generally circumferentially elongated, which results in a decreased pore size or a relatively “closed” configuration. In contrast, the pore size is increased or in a relatively “open” configuration when the device is in the longitudinally stretched configuration. In the longitudinally stretched configuration, many, if not all, of the pores of the device can be opened to an enlarged pore size, or to a generally maximum pore size.
For example, in some embodiments, the longitudinally stretched configuration can open the pores by orienting the individual filaments of the device to create a pattern of open-pore quadrilaterals, such as squares, rectangles, parallelograms, rhombuses, trapezoids, etc., which can allow the pore size to be generally maximized. Further, the quadrilaterals can be formed by filaments that cross at angles from about 0° to about 15° from a right angle. In some embodiments, the angles can be from about 0° to about 10° from a right angle. In some embodiments, the angles can be from about 0° to about 5° from a right angle. Additionally, in some embodiments, the filaments can form right-angled quadrilaterals, such as squares and rectangles, which allows the pore size to be maximized. However, not every pore shape circumscribed by the filaments may be a right-angled quadrilateral, and some variation between pores in the same or different sections of a device is possible.
Further, some embodiments of processes disclosed herein comprise dipping a longitudinally stretched braided device (e.g., stent) in a solvent and thereafter “air knifing” the dipped device to remove or blow off any excess solvent from the device. The air jet(s) of the air knife(s) can be applied in a direction that is generally transverse, such as orthogonal, relative to the longitudinal axis of the device. The air knife can be stationary while the device is moved, or it can move along or about the device as the device remains stationary.
Additionally, some embodiments also provide a coating fixture which can be used during the coating (e.g., dipping, spraying, etc.) processes to optimize the coating and drying process and prevent inadvertent wicking of the coating material away from the coated device (e.g. stent), which can result from undesired contact with the coated device (e.g., stent) during the process. Some embodiments of the coating fixture can be both rigid and/or lightweight. Further, in some embodiments, the coating fixture can comprise first and second ends that engage with corresponding ends of the device and a fixture body that extends between the first and second ends and outside of a device lumen when the device is mounted to the fixture. The first and second ends can be spaced apart sufficiently to maintain the device in a longitudinally stretched configuration when mounted on the cantilevered fixture.
The device (e.g., stent) can take the form of a vascular occluding device, a revascularization device and/or an embolization device. In some embodiments, the device can be an expandable stent made of two or more filaments. The filaments can be formed of known flexible materials including shape memory materials, such as nitinol, platinum and stainless steel. In some embodiments, the filaments can be round or ovoid wire. Further, the filaments can be configured such that the device is self-expanding. In some embodiments, the device can be fabricated from a first group of filaments made of platinum alloyed with 8% tungsten, and a second group of filaments made of 35N LT (cobalt nickel alloy, which is a low titanium version of MP35N alloy). In other embodiments, one or more of the filaments can be formed of a biocompatible metal material or a biocompatible polymer.
The wires or filaments can be braided into a resulting lattice-like structure. In at least one embodiment, during braiding or winding of the device (e.g., stent), the filaments can be braided using a 1-over-2-under-2 pattern. In other embodiments, however, other methods of braiding can be followed, without departing from the scope of the disclosure. The device can exhibit a porosity configured to reduce haemodynamic flow into and/or induce thrombosis within, for example, an aneurysm, but simultaneously allow perfusion to an adjacent branch vessel whose ostium is crossed by a portion of the device. As will be appreciated, the porosity of the device can be adjusted by “packing” the device during deployment, as known in the art. The ends of the device can be cut to length and therefore remain free for radial expansion and contraction. The device can exhibit a high degree of flexibility due to the materials used, the density (i.e., the porosity) of the filaments, and the fact that the ends of the wires or filaments are not secured to each other.
Information regarding additional embodiments, features, and other details of the devices, methods of use, and other components that can optionally be used or implemented in embodiments of the occlusion devices described herein, can be found in Applicants' co-pending applications U.S. patent application Ser. No. 12/751,997, filed on Mar. 31, 2010; Ser. No. 12/426,560, filed on Apr. 20, 2009; Ser. No. 11/136,395, filed May 25, 2005; Ser. No. 11/420,025, filed May 24, 2006; Ser. No. 11/420,027, filed May 24, 2006; Ser. No. 12/425,604, filed Apr. 17, 2009; Ser. No. 12/896,707, filed Oct. 1, 2010; 61/483,615, filed May 6, 2011; 61/615,183, filed Mar. 23, 2012; Ser. No. 13/614,349, titled Methods and Apparatus for Luminal Stenting, filed on Sep. 13, 2012 (reference HKN-02608 (1), 080373-0366); Ser. No. 13/692,021, titled Methods and Apparatus for Luminal Stenting, filed on Dec. 3, 2012 (reference HKN-02608 (2), 080373-0377); and Ser. No. 13/664,547, titled Methods and Apparatus for Luminal Stenting, filed on Oct. 31, 2012 (reference HKN-02608 (3), 080373-0498); the entireties of each of which are incorporated herein by reference.
In some embodiments, the pores of the flow diverting portion 112 can have an average pore size of less than 500 microns (inscribed diameter), or in the range of 20-300 microns (inscribed diameter). Further, the average pore size can be in the range of 25-250 microns (inscribed diameter). Furthermore, the average pore size can be in the range of 50-200 microns (inscribed diameter). The stent 100 can be expandable from an unexpanded diameter to an expanded diameter; the unexpanded diameter can optionally be 5 mm or less, or 4 mm or less, or 3 mm or less, or 2 mm or less, or other unexpanded diameters, and/or the expanded diameter can optionally be 2 mm or more, or 3 mm or more, or 4 mm or more, or 5 mm or more, or other expanded diameters. The unexpanded diameter can be less than the expanded diameter.
The average pore size of the pores in the flow diverting portion 112 can be the average size of the pores measured with or without coating material disposed thereon. Thus, the average pore size of the flow diverting portion of a bare stent can be within the flow diverting ranges. Further, the average pore size of the flow diverting portion of a coated stent can be within the flow diverting ranges. Furthermore, the flow diverting portion 112 can comprise pores having sizes above or below the range of the average pore size.
Accordingly, the size or configuration of the pore 140 is “closed” or relatively small in the expanded or relaxed state shown in
Additionally, in order to maximize the pore size, in some embodiments, the filaments can form right-angled quadrilaterals, such as squares and/or rectangles. However, not every pore shape circumscribed by the filaments may be a right-angled quadrilateral, and some variation between pores in the same or different sections of a stent is possible.
A device can be prepared according to some embodiments by braiding a plurality of filaments to form a braided stent, filter, or other braided device. The device can then be cleaned and heat treated, if necessary, to impart desired characteristics to the device. Thereafter, the device can be coated using aspects of the methods disclosed herein.
The handling system 180 is generally configured to rotate and move the stent 202 and mounting apparatus 210 vertically up and down. Thus the handling system 170 includes a powered linear actuator 172 that is oriented vertically and further includes a carriage 174 that can move up and down on, and under the power of, the linear actuator 172. On the carriage 174 is mounted an electric motor 176; when powered the motor 176 rotates a chuck 178. The chuck 178 detachably grips an upper end of the mounting apparatus 210 so that the motor 176 rotates the mounting apparatus 210 and stent 202 about a generally vertical axis when the motor 176 is energized.
The coating solution 260 is positioned beneath the motor 176 and mounting apparatus 210, and aligned generally with the mounting apparatus 210 and the rotational axis of the motor 176. Therefore, a downward movement of the carriage 174 (and with it the motor 176 and mounting apparatus 210) along the linear actuator 172 will cause the lower portions of the mounting apparatus 210 and stent 202 to be immersed in the coating solution 260 (see
The air knife 270 comprises a nozzle 271 that is connected via a hose to a source of pressurized air or other pressurized gas (not shown). The nozzle 271 is positioned and oriented so that, upon activation of the air knife 270, the nozzle directs an air jet or air stream 272 (see
The coating system 170 can be used to coat a stent generally as follows. The process begins with the coating system in the start position shown in
After air knifing is complete, the stent 202 is then raised out of the stream 272 via the actuator 172 (and/or the air knife 270 is deactivated), as shown for example in
More specific aspects of the coating system 170 and methods of coating will now be discussed in greater detail.
Enlarged views of the mounting apparatus 210, with the stent 202 mounted thereon, are illustrated in
Further, as shown in
The mounting apparatus 210 (see also
The depicted mounting apparatus 210 incorporates a number of design features that enable high-precision coating of the stent 100/202. The upper and lower fixtures 220, 222 are spaced apart so that the stent is held in a longitudinally stretched configuration and the pores are caused to take on the “open” configuration shown in
As illustrated in the enlarged view of the dipping procedure shown in
In a preferred embodiment of the above-described method and apparatus for coating a stent, the dimensions and process parameters shown in Table 1 below can be used for constructing the mounting apparatus 210 and performing the method.
Some of these parameters can be varied in other embodiments. For example, the air knife pressure could be 6-18 PSI, or 10-14 PSI; the distance from the nozzle to the stent could be 20-80 mm, or 40-70 mm; the stent rotation speed could be 50-150 RPM, or 80-120 RPM; the reciprocation speed could be 10-40 mm/s, or 18-30 mm/s; the amount of longitudinal stretch of the stent could be 1.5×-3×; the drying temperature could be 50-80 degrees C.; and/or the drying time could be 5-60 minutes. Although the air knife 270 is described as blowing air on the stent, other gases could be employed, such as nitrogen, argon or other relatively inert gases.
Other variations of the method and apparatus are possible. For example, multiple nozzles or gas sources could be used in the air knife 270 instead of the single nozzle 271 depicted and described above. The air knife 270 can move during the knifing process while the stent 202 remains stationary, rather than the reverse as described above. The backbone 240 can be made in a constant thickness or diameter that varies somewhat from that specified herein, or the backbone 240 can taper. For example, the backbone 240 can taper from a larger size at its upper end to a smaller size at its lower end.
Further, although dip coating and removal of excess coating material by air knife are discussed above, other coating methods can be implemented. For example, in some embodiments, the stent can be coated using a spray coating process. In spray coating, the coating material may be applied to the device using a spray coater.
Referring now to
In this embodiment, the filaments 300 cross each other in a generally orthogonal orientation relative to each other. As illustrated, the filaments 300 cross each other at angles of from about 75° to about 105°, or within from about 0° to about 15° from a right angle.
Generally, according to aspects of embodiments disclosed herein, when the filaments cross each other at substantially orthogonal or right angles (e.g., within about 15° from a right angle), the inter-filament space or crevice area (e.g., the gaps formed between surfaces of overlapping filaments at their crossing point) is minimized, thus reducing the space in which coating material can accumulate in excess of what is required to coat the filament surface. For example, an aspect of embodiments disclosed herein is the realization that the coating may be thicker in inter-filament spaces or crevices due to the surface tension of the coating material. Thus, reducing the inter-filament space can also reduce the amount of coating material captured therein by virtue of the coating material surface tension.
For example,
Some embodiments of the devices and methods disclosed herein can therefore provide a device, such as a stent or a braided stent, having a coating that is substantially free of webs, and in some embodiments, that also has a flow diverting pore size and/or a flow diverting porosity that is/are exhibited throughout the entire stent, or in a flow diverting portion or section of the stent. In one embodiment, a coated device, stent or section is “substantially free” of webs when any webs that are present are sufficiently few in number so as to not interfere with the function of the device. Alternatively, a coated device, stent or section that is substantially free of webs can be one in which there is webbing present at fewer than 5% of the filament crossing points, and/or at fewer than 5% of the pores. In another alternative, a coated device, stent or section that is substantially free of webs can be one in which there is webbing present at fewer than 3% of the filament crossing points, and/or at fewer than 3% of the pores. As yet another alternative, a coated device, stent or section can have no webbing at all in any of the filament crossing points, and/or in any of the pores.
Instead of or in addition to the substantial or complete absence of webbing discussed above, the coating of the device, stent or section can be substantially complete. Substantial completeness of coverage can be achieved when the filaments are covered completely along their length within the device, stent or section, with the exception of (a) uncoated areas amounting to less than 5%, or less than 3%, of the outer surface of the filaments, and/or (b) uncoated and/or less-coated (e.g. with fewer than all layers of a multi-layer coating) areas in some or all of the filament crossing points. Alternatively, the coated device, stent or section can be completely coated.
Instead of or in addition to the properties described above relating to lack of webs and/or completeness of coverage, the device, stent or section can be coated with an antithrombogenic coating sufficiently to reduce the thrombogenicity of the coated stent, device, section, etc. as compared to a similar but uncoated stent, device, section, etc. The reduction in thrombogenicity can be significant. Stents coated according to the method disclosed herein have been tested for increased antithrombogenicity via thrombogram, employing the following assay.
The citrated stock (˜240 ml) of platelet rich plasma (PRP) was stored on the rocker (setting: 2) at room temperature for 3 days (up to a maximum of 1 day post printed expiration date). PPP (platelet poor plasma) was prepared on day 1 of obtaining the corresponding PRP stock, as follows: (a) pour 100 mL of PRP stock suspension into two 50 mL centrifuge tubes; (b) centrifuge for 30 minutes at 2900×g; (c) carefully pour out the supernatant-platelet poor plasma (PPP) and filter it using a 0.22 μm syringe-driven filter unit; (d) divide some of the PPP into 5 mL aliquots; (e) store the PPP aliquots at −80° C.; and (e) utilize 50 mL of PPP for dilution of autologous PRP for purposes of the assay.
Next, Diluted PRP was prepared as follows: (a) perform platelet count (counting particles within size range of 2 μm-4 μm for PRP stock solution) in the particle counter by priming the aperture and cleaning the apparatus with purified water, diluting 10 μL of PRP stock in 10 mL of electrolyte solution and initiating the count, and recording the mean platelet count of the PRP stock; (b) dilute PRP to a final count of 200,000 per μL with autologous PPP; and (c) calculate total volume of PRP and PPP needed for assay (per sample=250 μL).
Samples of stents that were coated according to the method disclosed herein (“test stents”) and of identical but bare-metal stents (“bare stents”) were prepared as follows: (a) cut sections of each stent to a length of 9 mm; (b) immerse the sections individually in a 1.5 mL centrifuge tube filled with deionized water for 30 minutes; and (c) after wetting, blot out the excess water from each stent section on a kimwipe.
The 96-well microplate was then loaded with the following: (a) test stent sections (5 wells); (b) bare stent sections (5 wells); (c) 4 mm glass spheres (5 wells, to function as a positive control); and (d) blanks (5 wells with no samples, serving as a negative control). Only one of a test stent section, bare stent section or glass sphere was placed in any one well. The plate reader was then turned on and allowed to warm up for three minutes, while the associated PC software (Gen 5) was launched. The settings used were: test temperature 25° C.; fluorescence reading (excitation (nm): 360/40, emission (nm): 460/40); no shake; kinetic reading every one minute for each well; total experimental time of two hours. Generally, the plate reader was set up for immediate read before preparing the test solutions.
Test solutions were prepared immediately before the analysis as follows. Experimental solution was prepared by adding fluorogenic substrate (25 mg/mL)(40 mM) to Diluted PRP (final count 200,000/μL) in a 15 mL centrifuge tube for a final concentration of 400 μM, then adding 1M calcium chloride for a final concentration of 20 mM, and inverting the tube to mix. Calibrator solutions were prepared by (a) adding 1 mL of deionized water to a 1 mL vial (as packaged) of the lyophilized thrombin calibrator; (b) preparing 10 mL of HBS-BSA solution (20 mM HEPES, 10 mg/ml bovine serum albumin (BSA), pH 7.4, filtered with the 0.22 μm syringe filter); (c) making four serial dilutions of the calibrator as prepared in step (a), in HBS-BSA (1:2, 1:20, 1:200, 1:2000); (d) adding 100 μL of the fluorogenic substrate to 10 mL of PPP; and (e) mixing five calibrator solutions as follows: (1) by mixing fourteen parts of the substrate-PPP mixture of step (d) with one part of the 1:2 dilution of step (c); (2) by mixing fourteen parts of the substrate-PPP mixture of step (d) with one part of the 1:20 dilution of step (c); (3) by mixing fourteen parts of the substrate-PPP mixture of step (d) with one part of the 1:200 dilution of step (c); (4) by mixing fourteen parts of the substrate-PPP mixture of step (d) with one part of the 1:2000 dilution of step (c); and (5) by mixing fourteen parts of the substrate-PPP mixture of step (d) with one part of the (undiluted) calibrator as prepared in step (a).
The test solutions were transferred to the microplate as follows: (a) 300 μL of the experimental solution in each of the wells containing a test stent section, a bare stent section, or a glass sphere, and in each of the five designated blanks; and (b) 300 μL of calibrator solution in each of ten wells containing no sample (separate from the blank wells), two wells each for each of the five calibrator solutions described above. A multipipette dispenser was used for the experimental solution to ensure that all wells were filled in less than one minute.
The microplate was then placed the reader and the test was run. The coated stents were found to result in a significant delay in peak thrombin formation, as compared to a similar but uncoated stent. In particular, the elapsed time before peak thrombin formation was found to be about 2.5 times that of the similar but uncoated stent. In another experimental run, the elapsed time before peak thrombin formation was found to be about 1.5 times that of the similar but uncoated stent. Accordingly, the time before peak thrombin formation with the coated device, stent, section, etc. can be more than 1.5 times, or more than twice, or about 2.5 times, or about 1.5 times that of a similar but uncoated device, stent, section, etc.
The substantial or complete absence of webbing in the coated device, stent, section, etc. can be observed in SEM (scanning electron microscope) imaging.
Accordingly, instead of or in addition to the other coating properties discussed herein, the device, stent or section can have a coating weight gain in each of four longitudinal sections of the device, stent or section, wherein the weight gain varies by no more than 2.5 percentage points, or no more than 4 percentage points, or no more than 5 percentage points, between the largest and smallest gains among the four sections.
Braided tubular stents were coated according to the process described herein and the parameters provided in Table 1. Each of the stents was configured as follows: 48 braided filaments, of which 12 were of platinum alloyed with 8% tungsten, with 0.0012 inch filament diameter, 12 were of 35 NLT, with 0.0012 inch filament diameter, and 24 were of 35 NLT, with 0.0014 inch filament diameter; overall outside diameter 5.2 mm and longitudinal picks per inch of 275, both dimensions prevailing when in an expanded, unconstrained and unstretched condition.
The stents were provided in their “bare metal” condition, and prepared as follows. First, they were washed in 99.5% acetone for five minutes in an ultrasonic cleaner, and then washed in 99% isopropyl alcohol (IPA) in an ultrasonic cleaner, in two separate five-minute IPA wash stages. After washing, the stents were rinsed in distilled water and then dried in an oven at 60 degrees C. for 30 minutes.
A coating solution of 2-Methacryloyloxyethyl phosphorylcholine (MPC) was prepared by dissolving 2.0 grams of MPC (LIPIDURE™-CM2056) in 200 milliliters of ethanol, and provided in a beaker at room temperature. The coating process was then performed on each of the stents, according to the description provided herein and the parameters shown in Table 1. After completion of the process and trimming, the stents could be described as tubular braided stents, open at each end with a lumen extending from one end to the other, and with a coating of MPC over the entirety of the stent filaments.
Stents coated according to this Example 1 were tested for increased antithrombogenicity via thrombogram, employing the assay described above. The coated stents were found to result in a significant delay in peak thrombin formation, as compared to an identical but uncoated stent. In particular, the elapsed time before peak thrombin formation was found to be about 2.5 times the time observed with the identical but uncoated stent.
As mentioned elsewhere herein, the present disclosure also includes methods of treating a vascular condition, such as an aneurysm or intracranial aneurysm, with any of the embodiments of the coated stents disclosed herein. The coated, low-thrombogenicity stent could be deployed across the neck of an aneurysm and its flow-diverting properties employed to reduce blood flow between the aneurysm and the parent vessel, cause the blood inside the aneurysm to thrombose and lead to healing of the aneurysm.
Significantly, the low-thrombogenicity stents disclosed herein can facilitate treatment of a large population of patients for whom flow-diverter therapy has not been previously possible. Such patients are those who have previously suffered from a hemorrhagic aneurysm or who have been diagnosed as being at risk for hemorrhage from an aneurysm or other vascular anatomy such as from the intracranial arterial system. These patients cannot currently be treated with commercially available flow-diverting stents because those stents are bare metal, braided stents whose implantation requires the patient to take blood-thinning medication (typically aspirin and PLAVIX™ (clopidogrel)) for a long period of time following implantation. The purpose of the blood-thinning medication is to counteract the tendency of the bare-metal stent to cause thrombus (blood clots) to form in the patient's vasculature. However, for a patient who has suffered or is at risk of intracranial hemorrhage, taking the blood-thinning medication can cause, or put the patient at higher risk of, such a hemorrhage. Low-thrombogenicity flow-diverting stents, such as the coated stents disclosed herein, can make flow-diverter therapy possible for patients who cannot tolerate blood-thinning medication because the reduced thrombogenicity can reduce or eliminate the need for blood thinners.
In order to implant any of the coated stents disclosed herein, the stent can be mounted in a delivery system. Suitable delivery systems are disclosed in U.S. patent application Ser. No. 13/692,021, filed Dec. 3, 2012, titled METHODS AND APPARATUS FOR LUMINAL STENTING; and in U.S. Pat. No. 8,273,101, issued Sep. 25, 2012, titled SYSTEM AND METHOD FOR DELIVERING AND DEPLOYING AN OCCLUDING DEVICE WITHIN A VESSEL. The entire contents of both of these documents are incorporated by reference herein and made a part of this specification. In particular, these documents' teachings regarding braided stent delivery systems and methods may be employed to deliver any of the coated stents disclosed herein in the same manner, to the same bodily location(s), and using the same components as are disclosed in both incorporated documents.
Generally, as shown in
A treatment procedure can begin with obtaining percutaneous access to the patient's arterial system, typically via a major blood vessel in a leg or arm. A guidewire can be placed through the percutaneous access point and advanced to the treatment location, which can be in an intracranial artery. The microcatheter is then advanced over the guidewire to the treatment location and situated so that a distal open end of the guidewire is adjacent to the treatment location. The guidewire can then be withdrawn from the microcatheter and the core assembly, together with the stent mounted thereon or supported thereby, can be advanced through the microcatheter and out the distal end thereof. The stent can then self-expand into apposition with the inner wall of the blood vessel. Where an aneurysm is being treated, the stent is placed across the neck of the aneurysm so that a sidewall of the stent (e.g. a section of the braided tube) separates the interior of the aneurysm from the lumen of the parent artery. Once the stent has been placed, the core assembly and microcatheter are removed from the patient. The stent sidewall can now perform a flow-diverting function on the aneurysm, thrombosing the blood in the aneurysm and leading to healing of the aneurysm.
Because of the low-thrombogenic properties of the coated stents disclosed herein, certain additional aspects of the methods of treatment are possible. For example, the patient can be one who has previously suffered from, or who has been diagnosed as being at risk, of hemorrhage from an aneurysm or other arterial anatomy such as the intracranial arterial system. The patient can be prescribed a reduced regimen of blood-thinning medication as compared to the regimen that would be necessary for patient who received an otherwise similar but uncoated flow-diverting stent. The regimen can be “reduced” in the sense that the patient takes a lower dosage, fewer medications, less powerful medications, follows a lower dosage frequency, and/or takes medication for a shorter period of time following implantation of the stent, or otherwise. Alternatively, the patient may be prescribed no blood thinning medication at all.
The devices and methods discussed herein are not limited to the coating of stents, but may include any number of other implantable devices. Treatment sites may include blood vessels and areas or regions of the body such as organ bodies.
Although the detailed description contains many specifics, these should not be construed as limiting the scope of the subject technology but merely as illustrating different examples and aspects of the subject technology. It should be appreciated that the scope of the subject technology includes other embodiments not discussed in detail above. Various other modifications, changes and variations may be made in the arrangement, operation and details of the method and apparatus of the subject technology disclosed herein without departing from the scope of the present disclosure. Unless otherwise expressed, reference to an element in the singular is not intended to mean “one and only one” unless explicitly stated, but rather is meant to mean “one or more.” In addition, it is not necessary for a device or method to address every problem that is solvable by different embodiments of the disclosure in order to be encompassed within the scope of the disclosure.
This application is a continuation of U.S. patent application Ser. No. 15/404,760, filed on Jan. 12, 2017, which is a continuation of U.S. patent application Ser. No. 14/317,587, filed on Jun. 27, 2014, now patented as U.S. Pat. No. 9,545,301, which is a continuation-in-part of U.S. patent application Ser. No. 13/844,577, filed Mar. 15, 2013, now patented as U.S. Pat. No. 9,320,592, the entire contents of each of which are incorporated by reference herein and made a part of this specification.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3932627 | Margraf | Jan 1976 | A |
| 4656083 | Hoffman et al. | Apr 1987 | A |
| 4994071 | MacGreqor | Feb 1991 | A |
| 5013306 | Solomon et al. | May 1991 | A |
| 5019096 | Fox, Jr. et al. | May 1991 | A |
| 5217492 | Guire et al. | Jun 1993 | A |
| 5246451 | Trescony et al. | Sep 1993 | A |
| 5295979 | DeLaurentis et al. | Mar 1994 | A |
| 5360440 | Andersen | Nov 1994 | A |
| 5409696 | Narayanan et al. | Apr 1995 | A |
| 5419760 | Narciso, Jr. | May 1995 | A |
| 5449382 | Dayton | Sep 1995 | A |
| 5455040 | Marchant | Oct 1995 | A |
| 5464650 | Berg et al. | Nov 1995 | A |
| 5496276 | Wanq et al. | Mar 1996 | A |
| 5498248 | Milder | Mar 1996 | A |
| 5534287 | Lukic | Jul 1996 | A |
| 5567495 | Modak et al. | Oct 1996 | A |
| 5591140 | Narayanan et al. | Jan 1997 | A |
| 5591225 | Okuda | Jan 1997 | A |
| 5609629 | Fearnot et al. | Mar 1997 | A |
| 5616338 | Fox, Jr. et al. | Apr 1997 | A |
| 5618316 | Hoffman et al. | Apr 1997 | A |
| 5624411 | Tuch | Apr 1997 | A |
| 5624449 | Pham et al. | Apr 1997 | A |
| 5634941 | Winston et al. | Jun 1997 | A |
| 5643580 | Subramaniam | Jul 1997 | A |
| 5653747 | Dereume | Aug 1997 | A |
| 5665103 | Lafontaine et al. | Sep 1997 | A |
| 5667523 | Bynon et al. | Sep 1997 | A |
| 5674241 | Bley et al. | Oct 1997 | A |
| 5693085 | Buirge et al. | Dec 1997 | A |
| 5697971 | Fischell et al. | Dec 1997 | A |
| 5722984 | Fischell et al. | Mar 1998 | A |
| 5741327 | Frantzen | Apr 1998 | A |
| 5770255 | Burrell et al. | Jun 1998 | A |
| 5776141 | Klein et al. | Jul 1998 | A |
| 5824045 | Ait | Oct 1998 | A |
| 5824049 | Ragheb et al. | Oct 1998 | A |
| 5824077 | Mayer | Oct 1998 | A |
| 5837313 | Ding et al. | Nov 1998 | A |
| 5843117 | Alt et al. | Dec 1998 | A |
| 5866113 | Hendriks et al. | Feb 1999 | A |
| 5873904 | Ragheb et al. | Feb 1999 | A |
| 5888577 | Griffin, III et al. | Mar 1999 | A |
| 5897911 | Loeffler | Apr 1999 | A |
| 5902283 | Darouiche et al. | May 1999 | A |
| 5911754 | Kanesaka et al. | Jun 1999 | A |
| 5948018 | Dereume et al. | Sep 1999 | A |
| 5957974 | Thompson et al. | Sep 1999 | A |
| 5968069 | Dusbabek et al. | Oct 1999 | A |
| 5973068 | Yamaya et al. | Oct 1999 | A |
| 5976169 | Lmran | Nov 1999 | A |
| 6010530 | Goicoechea | Jan 2000 | A |
| 6019789 | Dinh et al. | Feb 2000 | A |
| 6022374 | Lmran | Feb 2000 | A |
| 6033719 | Keogh | Mar 2000 | A |
| 6048910 | Furuya et al. | Apr 2000 | A |
| 6051020 | Goicoechea et al. | Apr 2000 | A |
| 6066167 | Lau et al. | May 2000 | A |
| 6068634 | Lorentzen et al. | May 2000 | A |
| 6068656 | Von Oepen | May 2000 | A |
| 6106548 | Roubin et al. | Aug 2000 | A |
| 6156373 | Zhong et al. | Dec 2000 | A |
| 6159531 | Dang et al. | Dec 2000 | A |
| 6231598 | Berry et al. | May 2001 | B1 |
| 6268348 | Bhatnagar | Jul 2001 | B1 |
| 6306165 | Patnaik et al. | Oct 2001 | B1 |
| 6322847 | Zhong et al. | Nov 2001 | B1 |
| 6371980 | Rudakov et al. | Apr 2002 | B1 |
| 6461735 | Furuya et al. | Oct 2002 | B1 |
| 6652574 | Jayaraman | Nov 2003 | B1 |
| 6663660 | Dusbabek et al. | Dec 2003 | B2 |
| 6706024 | Modak et al. | Mar 2004 | B2 |
| 6979348 | Sundar | Dec 2005 | B2 |
| 7077860 | Yan et al. | Jul 2006 | B2 |
| 7198675 | Fox et al. | Apr 2007 | B2 |
| 7258891 | Pacetti et al. | Aug 2007 | B2 |
| 7297159 | Hossainy et al. | Nov 2007 | B2 |
| RE40722 | Chappa | Jun 2009 | E |
| 7553377 | Chen et al. | Jun 2009 | B1 |
| 7563277 | Case et al. | Jul 2009 | B2 |
| 7563324 | Chen et al. | Jul 2009 | B1 |
| 7572336 | Van Sciver et al. | Aug 2009 | B2 |
| 7588642 | Morris et al. | Sep 2009 | B1 |
| 7604700 | Fox et al. | Oct 2009 | B2 |
| 7622070 | Atladottir et al. | Nov 2009 | B2 |
| 7632307 | Pacetti et al. | Dec 2009 | B2 |
| 7648725 | Van Sciver et al. | Jan 2010 | B2 |
| 7669548 | Chappa | Mar 2010 | B2 |
| 7704544 | Pacetti et al. | Apr 2010 | B2 |
| 7735449 | Harold et al. | Jun 2010 | B1 |
| 7771743 | Luthra et al. | Aug 2010 | B1 |
| 7820284 | Terry et al. | Oct 2010 | B2 |
| 7823533 | Chen et al. | Nov 2010 | B2 |
| 7833544 | Lewis et al. | Nov 2010 | B2 |
| 7939095 | Zhao | May 2011 | B2 |
| 7958840 | Chappa | Jun 2011 | B2 |
| 7959942 | Cottone | Jun 2011 | B2 |
| 7985440 | Pacetti et al. | Jul 2011 | B2 |
| 7985441 | Tang et al. | Jul 2011 | B1 |
| 8003156 | Van Sciver | Aug 2011 | B2 |
| 8069814 | Guerriero et al. | Dec 2011 | B2 |
| 8097291 | Fredrickson et al. | Jan 2012 | B2 |
| 8152841 | Molaei et al. | Apr 2012 | B2 |
| 8188180 | Jonschker et al. | May 2012 | B2 |
| 8197879 | Fox et al. | Jun 2012 | B2 |
| 8221495 | Shrivastava et al. | Jul 2012 | B2 |
| 8267986 | Berez et al. | Sep 2012 | B2 |
| 8273101 | Garcia et al. | Sep 2012 | B2 |
| 8282979 | Larson et al. | Oct 2012 | B2 |
| 8308699 | Zhang et al. | Nov 2012 | B2 |
| 8398701 | Berez et al. | Mar 2013 | B2 |
| 8409269 | Berez et al. | Apr 2013 | B2 |
| 8506619 | Ortiz | Aug 2013 | B2 |
| 8591566 | Newell et al. | Nov 2013 | B2 |
| 8617234 | Garcia et al. | Dec 2013 | B2 |
| 8628564 | Berez et al. | Jan 2014 | B2 |
| 8668919 | Ludwig et al. | Mar 2014 | B2 |
| 8690907 | Janardhan et al. | Apr 2014 | B1 |
| 8778008 | Amplatz et al. | Jul 2014 | B2 |
| 8789452 | Janardhan et al. | Jul 2014 | B1 |
| 8801777 | Elmaleh | Aug 2014 | B2 |
| 9034026 | Hannes et al. | May 2015 | B2 |
| 9039749 | Shrivastava et al. | May 2015 | B2 |
| 9320592 | Wainwright et al. | Apr 2016 | B2 |
| 9545301 | Wainwright et al. | Jan 2017 | B2 |
| 9668890 | Ma et al. | Jun 2017 | B2 |
| 10226366 | Wainwright et al. | Mar 2019 | B2 |
| 20010047202 | Slaikeu et al. | Nov 2001 | A1 |
| 20020058988 | Fischel et al. | May 2002 | A1 |
| 20020062145 | Rudakov et al. | May 2002 | A1 |
| 20030033007 | Sirhan et al. | Feb 2003 | A1 |
| 20030050691 | Shifrin et al. | Mar 2003 | A1 |
| 20040185081 | Verlee et al. | Sep 2004 | A1 |
| 20040236399 | Sundar | Nov 2004 | A1 |
| 20040249437 | Sundar | Dec 2004 | A1 |
| 20040254634 | Verlee et al. | Dec 2004 | A1 |
| 20050015142 | Austin et al. | Jan 2005 | A1 |
| 20050022915 | Bowen et al. | Feb 2005 | A1 |
| 20050060028 | Horres et al. | Mar 2005 | A1 |
| 20050107869 | Sirhan et al. | May 2005 | A1 |
| 20050137680 | Ortiz et al. | Jun 2005 | A1 |
| 20050158449 | Chappa | Jul 2005 | A1 |
| 20050175660 | Mollison et al. | Aug 2005 | A1 |
| 20050179011 | van Ooij et al. | Aug 2005 | A1 |
| 20050182474 | Jones et al. | Aug 2005 | A1 |
| 20060047336 | Gale et al. | Mar 2006 | A1 |
| 20060052757 | Fischer et al. | Mar 2006 | A1 |
| 20060088653 | Chappa | Apr 2006 | A1 |
| 20060177476 | Saffran | Aug 2006 | A1 |
| 20060206200 | Garcia et al. | Sep 2006 | A1 |
| 20070003753 | Asgari | Jan 2007 | A1 |
| 20070043428 | Jennings et al. | Feb 2007 | A1 |
| 20070050007 | Kondyurin et al. | Mar 2007 | A1 |
| 20070168019 | Amplatz et al. | Jul 2007 | A1 |
| 20070189915 | Shrivastava et al. | Aug 2007 | A1 |
| 20080033522 | Grewe et al. | Feb 2008 | A1 |
| 20080143659 | Ma | Jun 2008 | A1 |
| 20080145393 | Trollsas et al. | Jun 2008 | A1 |
| 20080188830 | Rosenblatt et al. | Aug 2008 | A1 |
| 20080206829 | Yu et al. | Aug 2008 | A1 |
| 20090011117 | Nunez et al. | Jan 2009 | A1 |
| 20090029961 | Modak et al. | Jan 2009 | A1 |
| 20090062899 | Dang et al. | Mar 2009 | A1 |
| 20090155335 | O'Shaughnessey et al. | Jun 2009 | A1 |
| 20090254174 | Case et al. | Oct 2009 | A1 |
| 20090312834 | Wood et al. | Dec 2009 | A1 |
| 20100131044 | Patel | May 2010 | A1 |
| 20100152834 | Hannes et al. | Jun 2010 | A1 |
| 20100179644 | Jennings et al. | Jul 2010 | A1 |
| 20100189808 | Gupta et al. | Jul 2010 | A1 |
| 20100191219 | Gupta et al. | Jul 2010 | A1 |
| 20100196434 | Gupta et al. | Aug 2010 | A1 |
| 20100198334 | Yodfat et al. | Aug 2010 | A1 |
| 20100215711 | Gupta et al. | Aug 2010 | A1 |
| 20100226955 | Ludwig et al. | Sep 2010 | A1 |
| 20100233288 | Gupta et al. | Sep 2010 | A1 |
| 20100234815 | Do et al. | Sep 2010 | A1 |
| 20100280587 | Ortiz et al. | Nov 2010 | A1 |
| 20110000658 | Tanaka et al. | Jan 2011 | A1 |
| 20110022149 | Cox et al. | Jan 2011 | A1 |
| 20110027757 | Kyomoto et al. | Feb 2011 | A1 |
| 20110039013 | Papp et al. | Feb 2011 | A1 |
| 20110054589 | Bashiri et al. | Mar 2011 | A1 |
| 20110152998 | Berez et al. | Jun 2011 | A1 |
| 20110208294 | Cottone | Aug 2011 | A1 |
| 20120021038 | Kloke et al. | Jan 2012 | A1 |
| 20120164458 | Biteau et al. | Jun 2012 | A1 |
| 20120197413 | Kyomoto et al. | Aug 2012 | A1 |
| 20120253369 | Morsi | Oct 2012 | A1 |
| 20120271396 | Zheng et al. | Oct 2012 | A1 |
| 20120283765 | Berez et al. | Nov 2012 | A1 |
| 20120301528 | Uhlmann et al. | Nov 2012 | A1 |
| 20120301530 | Uhlmann et al. | Nov 2012 | A1 |
| 20120303112 | Armstrong et al. | Nov 2012 | A1 |
| 20130226276 | Newell et al. | Aug 2013 | A1 |
| 20130226278 | Newell et al. | Aug 2013 | A1 |
| 20130231400 | Kim | Sep 2013 | A1 |
| 20130245745 | Vong et al. | Sep 2013 | A1 |
| 20130253572 | Molaei et al. | Sep 2013 | A1 |
| 20130304185 | Newell et al. | Nov 2013 | A1 |
| 20130315972 | Krasnow et al. | Nov 2013 | A1 |
| 20140277400 | Wainwright et al. | Sep 2014 | A1 |
| 20150066128 | Losordo et al. | Mar 2015 | A1 |
| 20150081003 | Wainwright et al. | Mar 2015 | A1 |
| 20150140344 | Ma et al. | May 2015 | A1 |
| 20150148882 | Ma et al. | May 2015 | A1 |
| 20160051263 | Morsi | Feb 2016 | A1 |
| 20170119557 | Wainwright et al. | May 2017 | A1 |
| 20170232156 | Ma et al. | Aug 2017 | A1 |
| 20190125555 | Ma et al. | May 2019 | A1 |
| Number | Date | Country |
|---|---|---|
| 2683969 | Oct 2008 | CA |
| 1678366 | Oct 2005 | CN |
| 1309353 | Apr 2007 | CN |
| 101212938 | Jul 2008 | CN |
| 101212990 | Jul 2008 | CN |
| 101234046 | Aug 2008 | CN |
| 101264346 | Sep 2008 | CN |
| 101677867 | Mar 2010 | CN |
| 102573701 | Jul 2012 | CN |
| 102579170 | Jul 2012 | CN |
| 19535068 | Mar 1997 | DE |
| 1000591 | May 2000 | EP |
| 1550477 | Jul 2005 | EP |
| 1883380 | Mar 2010 | EP |
| 2003290360 | Oct 2003 | JP |
| 2004526499 | Sep 2004 | JP |
| 2006051498 | Feb 2006 | JP |
| 2006521881 | Sep 2006 | JP |
| 2007236399 | Sep 2007 | JP |
| 2007536991 | Dec 2007 | JP |
| 2008518671 | Jun 2008 | JP |
| 2008173461 | Jul 2008 | JP |
| 2009502420 | Jan 2009 | JP |
| 2009240490 | Oct 2009 | JP |
| 2011525137 | Sep 2011 | JP |
| 2012523922 | Oct 2012 | JP |
| 2012527912 | Nov 2012 | JP |
| 10-2008-0067953 | Jul 2008 | KR |
| WO 9102537 | Mar 1991 | WO |
| WO 9810806 | Mar 1998 | WO |
| WO 9937242 | Jul 1999 | WO |
| WO 2000047134 | Aug 2000 | WO |
| WO 2000061034 | Oct 2000 | WO |
| WO 2002074194 | Sep 2002 | WO |
| WO 2003017852 | Mar 2003 | WO |
| WO 2004087017 | Oct 2004 | WO |
| WO 2005065579 | Jul 2005 | WO |
| WO 2005112570 | Dec 2005 | WO |
| WO 2006118863 | Nov 2006 | WO |
| WO 2007018980 | Feb 2007 | WO |
| WO 2008118132 | Oct 2008 | WO |
| WO 2009081870 | Feb 2009 | WO |
| WO 2010136075 | Dec 2010 | WO |
| WO 2013030819 | Mar 2013 | WO |
| WO 2014152608 | Sep 2014 | WO |
| Entry |
|---|
| Bilgili et al., “Nano-milling of pigment agglomerates using a wet stirred media mill: Elucidation of the kinetics and breakage mechanisms”, Chem. Eng. Sci. 2006; available online Jun. 21, 2005; (61(1)), pp. 149-157. |
| BiodivYsio PMA POOOOII Summary of Safety and Effectiveness Data, Biocompalibles Cardiovascular Inc., Sep. 29, 2000, 26 pp. |
| Bridges et al., “Advances in drug eluting stents—focus on the Endeavor® zotarolimus stent,” Medical Devices: Evidence and Research, Dec. 7, 2008, pp. 1-8. |
| Chen et al., “Surfaces having dual fibrinolytic and protein resistant properties by immobilization of lysine on polyurethane through a PEG spacer,” Journal of Biomedical Materials Research Part A, Jul. 21, 2008, pp. 940-946. |
| Dow Corning, “A Guide to Silane Solutions,” Dow Coming, 2005, accessed on Dec. 16, 2014; 30 pp. |
| Dumitriu, “Polymeric Biomalerials: Structure and Function,” Table 25.6, CRC Press, Dec. 15, 2011, 1 pp. |
| Ehlers et al., “Theoretical Study on Mechanisms of the Epoxy-Amine Curing Reaction,” Macromolecules, vol. 40, May 19, 2007, pp. 4370-4377. |
| Endeavor PMA P060033 Summary of Safety and Effectiveness Data, Medlronic Vascular, 2007, accessed on Dec. 16, 2014; 59 pp. |
| Examination Report from counterpart European Application No. 14719476.5, dated Mar. 9, 2017, 5 pp. |
| Examination Report from counterpart European Application No. 14719476.5, dated Oct. 20, 2016, 7 pp. |
| First Office Action and Search Report, and translation thereof, from counterpart Chinese Application No. 201480015573.X, dated May 5, 2016, 24 pp. |
| First Office Action and Search Report, and translation thereof, from counterpart Chinese Application No. 201710819642.8, dated Oct. 29, 2018, 21 pp. |
| Feng et al., “Atom-Transfer Radical Grafting Polymerization of 2-Methacryloyloxyethyl Phosphorylcholine from Silicon Wafer Surfaces,” Journal of Polymer Science: Part A: Poymer Chemistry, vol. 42, Jan. 23, 2004, pp. 2931-2942. |
| Fu et al., “Surface Modification of Small Platinum Nanoclusters with Alkylamine and Alkylthiol: An KPS Study on the Influence of Organic Ligands on the PI 4f Binding Energies of Small Platinum Nanoclusters,” Journal of Colloid and Interface Science, Nov. 2001, vol. 243, Issue 2, pp. 326-330. |
| Gelest, Inc., “Silane Coupling Agents: Connecting Across Boundaries,” version 2, 2006, accessed on Dec. 16, 2014; 59 pp. |
| “A Guide to Silane Solutions from Dow Corning,” Dow Corning Corporation, 2005, 32 pp. (Applicant points out that, in accordance with MPEP 609.04(a), the 2005 year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date of Nov. 22, 2013 so that the particular month of publication is not in issue.) |
| Intent to Grant from counterpart European Patent Application No. 14719476.5, dated Nov. 14, 2017, 118 pp. |
| International Preliminary Report on Patentability from International Application No. PCT/US2014/027526, dated Sep. 15, 2015, 7 pp. |
| International Preliminary Report on Patentability from International Application No. PCT/US2015/037886, dated Apr. 13, 2017, 8 pp. |
| International Search Report and Written Opinion from International Application No. PCT/US2014/027526, dated Jul. 28, 2014, 10 pp. |
| Kang et al., “Fabrication of biofunctional stents with endothelial progenitor cell specificity for vascular re-endothelialization,” Colloids and Surfaces B: Biointerfaces, vol. 102, Sep. 17, 2012, pp. 744-751. |
| Lee et al., “Covalent incorporation of starch derivative into waterborne polyurethane for biodegradability,” Carbohydrate Polymers, vol. 87, Oct. 6, 2011, pp. 1803-1809. |
| Lewis et al., “Poly(2-methacryloyloxyethyl phosphorylcholine) for Protein Conjugation,” Bioconjugate Chemistry, vol. 19, Sep. 19, 2008, pp. 2144-2155. |
| Lin et al., “Surface characterization and platelet adhesion studies on polyurethane surface immobilized with C60,” Biomaterials, vol. 20, Mar. 31, 1999, pp. 1613-1620. |
| Love et al., “Self-Assembled Monolayers of Thiolates on Metals as a Form of Nanotechnology,” Chem, Rev, vol. 105, Mar. 25, 2005, pp. 1103-1169. |
| Luzinov, et al., “Epoxy-Terminated Self-Assembled Monolayers: Molecular Glues for Polymer La ers,” Lan muir, 2000, received Apr. 26, 1999; vol. 16, pp. 504-516. |
| McAuliffe et al., “Immediate and Midterm Results following Treatment of Recently Ruptured Intracranial Aneurysms with the Pipeline Embolization Device,” AJNR, Am J. Neuroradiol, vol. 33, Mar. 2012, pp. 487-493. |
| Notice of Allowance, and translation thereof, from counterpart Chinese Application No. 201480015573.X, dated Jun. 29, 2017, 3 pp. |
| Notice of Final Rejection, and translation thereof, from counterpart Japanese Application No. 2016-502472, dated Jan. 17, 2017, 7 pp. |
| Notice of Final Rejection, and translation thereof, from counterpart Korean Application No. 10-2015-7024827, dated Apr. 3, 2017, 5 pp. |
| Notice of Pre-Appeal Examination Report, and translation thereof, from counterpart Japanese Application No. 2016-502472, dated Jul. 14, 2017, 7 pp. |
| Notice of Preliminary Rejection, and translation thereof, from counterpart Korean Application No. 10-2015-7024827, dated May 23, 2016, 6 pp. |
| Notice of Preliminary Rejection, and translation thereof, from counterpart Korean Application No. 10-2015-7024827, dated Jan. 2, 2017, 10 pp. |
| Notice of Reasons for Rejection, and translation thereof, from counterpart Japanese Application No. 2016-502472, dated Apr. 25, 2016, 13 pp. |
| Notice of Reasons for Rejection, and translation thereof, from counterpart Japanese Application No. 2017098118, dated Mar. 29, 2018, 10 pp. |
| The Notification of Reason for Rejection, and translation thereof, from counterpart Japanese Application No. 2016-502472, dated Sep. 26, 2018, 13 pp. |
| “Product description for Lipidure-PC (MPC monomer) retrieved on Sep. 10, 2015, from http://nofamerica. net/store/index. ph p?dispatch=categories.view&category_id= 145”. |
| “Product description for Lipidure-CM (MPC polymer) retrieved on Apr. 9, 2013, from http://nofamerica. net/store/index. ph p?dispatch=categories. view&category_id= 146”. |
| “Product description for Reactive MPC Polymers retrieved on Sep. 10, 2015, from http://nofamerica. net/store/index. ph p?dispatch=categories. view&category_id=212”. |
| Prosecution History from U.S. Appl. No. 13/844,577, dated Jul. 1, 2014 through Jan. 25, 2016, 67 pp. |
| Prosecution History from U.S. Appl. No. 14/317,587, dated Dec. 23, 2015 through Dec. 8, 2016, 55 pp. |
| Prosecution History from U.S. Appl. No. 15/404,760, dated Jan. 13, 2017 through Dec. 19, 2018, 41 pp. |
| Ren et al., “Hemocompatibility Evaluation of Polyurethane Film with Surface-Grafted Poly (ethylene glycol) and Carboxymethyl-Chitosan,” Journal of Applied Polymer Science, May 4, 2012, pp. 308-315. |
| Report of Reconsideration by Examiner before Appeal, and machine translation thereof, from counterpart Japanese No. 2016-502472, dated Jul. 14, 2017, 6 pp. |
| Sanchis et al., “Surface Modification of a Polyurethane Film by Low Pressure Glow Discharge Oxygen Plasma Treatment,” Journal of Applied Polymer Science, vol. 105, Apr. 9, 2007, pp. 1077-1085. |
| The Second Notification of Reason for Rejection, and translation thereof, from counterpart Korean Application No. 10-2015-7024827, dated Jun. 7, 2017, 5 pp. |
| Second Office Action, and machine translation thereof, from counterpart Chinese Application No. 201480015573.X, dated Mar. 1, 2017, 7 pp. |
| Sidouni et al., “Surface properties of a specifically modified high-grade medical polyurethane,” Surface Science, vol. 491, Apr. 26, 2001, pp. 355-369. |
| “Summary of Safety and Effectiveness Data,” Oct. 10, 2007, 59 pp. |
| Troughton, et al., “Monolayer Films Prepared by the Spontaneous Self-Assembly of Symmetrical and Unsymmetrical Dialkyl Sulfides from Solution onto Gold Substrates: Structure, Properties, and Reactivity of Constituent Functional Groups,” Langmuir, 1988, vol. 4, pp. 365-385. |
| Tsukruk et al., “Sticky Molecular Surfaces: Epoxysilane Self-Assembled Monolayers,” Langmuir, vol. 15, Apr. 1, 1999, pp. 3029-3032. |
| Yakai et al., “Surface Modification of Polycarbonate Urethane by Covalent Linkage of Heparin with a PEG Spacer,” Tianjin University and Springer-Verlag Berlin Heidelberg, vol. 19, Feb. 9, 2013, pp. 58-65. |
| Zhang et al., “Superlow Fouling Sulfobetaine and Carboxybetaine Polymers on Glass Slides,” Langmuir, Vol: 22, Oct. 28, 2006, pp. 10072-10077. |
| Second Office Action and Search Report, and translation thereof, from counterpart Chinese Application No. 201710819642.8, dated Jul. 12, 2019, 11 pp. |
| U.S. Appl. No. 16/586,639, filed Sep. 27, 2019, by Ma et al. |
| Examination Report, and translation thereof, from counterpart Indian Application No. 8250/DELNP/2015, dated Dec. 24, 2019, 6 pp. |
| Notice of Preliminary Rejection, and translation thereof, from counterpart Korean Application No. 10-2017-7018628, dated Dec. 9, 2019, 6 pp. |
| Office Action and Search Report, and informal translation thereof, from counterpart Brazilian Application No. BR112015020893-2, dated Jan. 17, 2020, 5 pp. |
| Number | Date | Country | |
|---|---|---|---|
| 20190175373 A1 | Jun 2019 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15404760 | Jan 2017 | US |
| Child | 16277170 | US | |
| Parent | 14317587 | Jun 2014 | US |
| Child | 15404760 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 13844577 | Mar 2013 | US |
| Child | 14317587 | US |
